Oncology biotech Parabilis Medicines raised $670 million, pricing its IPO at $20 per share, above its targeted range.
The big picture: Parabilis' offering could rank among the largest biotech IPOs ever, just months after obesity biotech Kailera Therapeutics raised $625 million.
